For
the quarter ending dec 2022, standalone Net sales (including other operating income) of Pfizer has declined 8.01% to Rs 621.75 crore compared to quarter ended Dec 2021. Operating profit margin has jumped from 28.88% to 32.72%, leading to 4.24% rise in operating profit to Rs 203.45 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 13.24% to 15.66%. Purchase of finished goods cost fell from 15.19% to 13.91%. Employee cost decreased from 18.54% to 15.96%. Other expenses fell from 20.05% to 19.05%. Other income up 50.11% to Rs 27.41 crore. PBIDT rose 8.17% to Rs 230.86 crore. Provision for interest up 76.15% to Rs 3.84 crore.
PBDT rose 7.47% to Rs 227.02 crore. Provision for depreciation down 3.02% to Rs 26.34 crore.
Profit before tax grew 9.01% to Rs 200.68 crore. Provision for tax was expense of Rs 50.02 crore, compared to Rs 40.18 crore. Effective tax rate was 24.93% compared to 21.83%.
Profit after tax rose 4.69% to Rs 150.66 crore.
Promoters’ stake was 63.92% as of 31 December 2022 ,compared to 63.92% as of 31 December 2021 .
For year-to-date (YTD) results analysis
Net sales (including other operating income) of Pfizer has declined 10.15% to Rs 1,852.12 crore.
Operating profit margin has jumped from 32.52% to 33.85%, leading to 6.46% decline in operating profit to Rs 626.99 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 13.26% to 15.34%. Purchase of finished goods cost fell from 22.61% to 17.93%. Employee cost decreased from 15.33% to 14.88%. Other expenses rose from 15.82% to 16.82%. Other income up 53.02% to Rs 69.67 crore. PBIDT fell 2.68% to Rs 696.66 crore. Provision for interest up 63.55% to Rs 10.86 crore.
PBDT fell 3.30% to Rs 685.8 crore. Provision for depreciation down 2.81% to Rs 79.1 crore. Profit before tax down 3.36% to Rs 606.70 crore. Provision for tax was expense of Rs 165.01 crore, compared to Rs 141.01 crore. Effective tax rate was 25.03% compared to 22.46%.Profit after tax rose 1.54% to Rs 494.28 crore. Promoters’ stake was 63.92% as of 31 December 2022 ,compared to 63.92% as of 31 December 2021 .
Full year results analysis
Net sales (including other operating income) of Pfizer has increased 16.64% to Rs 2,610.99 crore. Operating profit margin has jumped from 31.81% to 32.01%, leading to 17.36% rise in operating profit to Rs 835.73 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.05% to 13.20%. Purchase of finished goods cost rose from 20.17% to 24.84%. Employee cost decreased from 16.23% to 15.04%. Other expenses fell from 16.53% to 15.78%. Other income fell 22.77% to Rs 62.65 crore. PBIDT rose 13.25% to Rs 898.38 crore. Provision for interest fell 30.58% to Rs 10.49 crore. Loan funds declined from Rs 63.23 crore as of 31 March 2021 to Rs 39.25 crore as of 31 March 2022. Inventories rose to Rs 448.90 crore as of 31 March 2022 from Rs 435.05 crore as of 31 March 2021. Sundry debtors were higher at Rs 124.27 crore as of 31 March 2022 compared to Rs 108.77 crore as of 31 March 2021. Cash and bank balance rose to Rs 1,633.33 crore as of 31 March 2022 from Rs 1,115.10 crore as of 31 March 2021.
PBDT rose 14.11% to Rs 887.89 crore. Provision for depreciation rose 5.11% to Rs 115 crore. Fixed assets increased to Rs 248.24 crore as of 31 March 2022 from Rs 224.70 crore as of 31 March 2021. Intangible assets declined from Rs 672.36 crore to Rs 622.04 crore.
Profit before tax grew 15.58% to Rs 772.89 crore. Provision for tax was expense of Rs 160.33 crore, compared to Rs 171.11 crore. Effective tax rate was 20.74% compared to 25.59%.
Profit after tax rose 23.10% to Rs 612.56 crore.
Promoters’ stake was 63.92% as of 31 March 2022 ,compared to 63.92% as of 31 March 2021 .
Cash flow from operating activities increased to Rs 667.08 crore for year ended March 2022 from Rs 427.33 crore for year ended March 2021. Cash flow used in acquiring fixed assets during the year ended March 2022 stood at Rs 15.31 crore, compared to Rs 17.70 crore during the year ended March 2021.
Other Highlights
Board considered the
recommendation of the Nomination & Remuneration Committee and approved the
appointment of Meenakshi as the Managing Director w.e.f. 3rd April 2023. S.
Sridhar the current India Country President will be stepping down as Managing
Director and Member of Board close of business hours on 31st March 2023.